Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 17fludarabine phosphate 14Whole-Body Irradiation 11Mycophenolic Acid 9Epoetin Alfa 9Cyclosporine 9Busulfan 9fludarabine 8Cord Blood Stem Cell Transplantation 8Antilymphocyte Serum 8Filgrastim 6Tacrolimus 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Methotrexate 5Darbepoetin alfa 5Dalteparin 5Cytarabine 5eltrombopag 4Tinzaparin 4Thiotepa 4Platelet Transfusion 4Melphalan 4Etoposide 4Arsenic Trioxide 4thymoglobulin 3epoetin beta 3Vorinostat 3Transplantation 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × lintuzumab × Classical hematology × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡